LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤Cash, cash equivalents and investments $32.3 million versus $88.3 million at December 31, 2025
- ➤Net loss $21.2 million, or $0.89 per share, versus $6.6 million loss
- ➤R&D expenses $14.6 million, driven primarily by ELAINE-3 clinical trial spending
- ➤ELAINE-3 enrollment targeted for completion in the fourth quarter of 2026
- ➤ELAINE-2 combination study showed approximately 13-month median progression-free survival and 56% objective response rate
Expert Statements
Mark Litton, President and Chief Executive Officer of LeonaBio
“We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026,”
Mark Litton, President and Chief Executive Officer of LeonaBio
“With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene. Our efforts extend beyond clinical execution as we advance regulatory, manufacturing and commercial readiness activities designed to support a potential launch and maximize the opportunity to bring this important therapy to patients as efficiently as possible.”
Mark Litton, President and Chief Executive Officer of LeonaBio
“We believe lasofoxifene has the potential to redefine treatment for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, a population that continues to face disease progression despite advances in care. The compelling body of clinical and scientific evidence generated to date, including encouraging efficacy and tolerability findings from our Phase 2 studies, reinforces our confidence in the program and its potential to become a new standard of care.”
BOTHELL, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended September 30, 2026, and provided recent pipeline and business updates.
“We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene. Our efforts extend beyond clinical execution as we advance regulatory, manufacturing and commercial readiness activities designed to support a potential launch and maximize the opportunity to bring this important therapy to patients as efficiently as possible.”
Get started
Create a free account to read the full story.
